- Push-out Score determined
- After less than two and a half years in the position
- Praise for Meyenburg
- Georges Gemayel taking over temporarily
(exechange) — Cambridge, Massachusetts, February 28, 2022 — Jason Meyenburg, chief executive of Gemini Therapeutics, leaves. As announced by Gemini Therapeutics Inc. in a news release and in a regulatory filing published on Monday, February 28, 2022, Jason Meyenburg leaves his post as chief executive officer at the clinical stage precision medicine company, after less than two and a half years in the role, effective immediately.
Jason Meyenburg’s duties as CEO will be taken over temporarily by Georges Gemayel, most recently Executive Chair at Gemini Therapeutics Inc., as interim Chief Executive Officer.
No reason given
In the announcement, Gemini Therapeutics did not explicitly explain the reason for the move.
Precise information regarding Jason Meyenburg’s future plans was not immediately available.
Gemini Therapeutics said: “The Board of Directors has appointed Georges Gemayel, Ph.D., the Company’s current Executive Chair, as interim President and Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company.”
Gemini Therapeutics further said: “Mr. Meyenburg’s last date of employment with the Company as its President and Chief Executive Officer is February 28, 2022 (the “Separation Date”). Mr. Meyenburg will no longer serve as a director of the Company, effective as of February 28, 2022.”
“Not due to any disagreement”
“Mr. Meyenburg’s resignation from the Board was not due to any disagreement with the Company’s operations, policies or practices,” Gemini Therapeutics said.
Share price decline since February 2021
The announcement follows a decline in Gemini Therapeutics Inc.’s share price of 89% since February 2021.
In the position of CEO since 2019
Jason Meyenburg became CEO of the Company in 2019.
Jason Meyenburg has served as the Company’s Chief Executive Officer since September 2019.
Previously, from March 2018 to September 2019, Meyenburg served as Chief Commercial Officer of Orchard Therapeutics plc, a publicly-traded biotechnology.
Before that, Meyenburg served as the Chief Commercial Officer of Sucampo Pharmaceuticals, Inc. from April 2017 to March 2018.
Prior to that, Meyenburg served as the Chief Commercial Officer of Vtesse, Inc., which became a wholly-owned subsidiary of Sucampo in April 2017, from December 2016 to April 2017.
Additionally, from January 2003 to February 2016, Meyenburg held roles of increasing responsibility at Alexion Pharmaceuticals, Inc., a publicly-traded biotechnology company, including as the Senior Vice President of Commercial Operations for the Americas.
Meyenburg holds an M.B.A. from Duke University and a B.S. in Biochemistry from University of Maryland.
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding Jason Meyenburg’s move on a scale of 0 to 10.
exechange reached out to Gemini Therapeutics and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 10.2022 ($).